AR046728A1 - Antagonistas de factor de transcripcion de la forma corta de c-maf para el tratamiento del glaucoma - Google Patents
Antagonistas de factor de transcripcion de la forma corta de c-maf para el tratamiento del glaucomaInfo
- Publication number
- AR046728A1 AR046728A1 ARP040104413A ARP040104413A AR046728A1 AR 046728 A1 AR046728 A1 AR 046728A1 AR P040104413 A ARP040104413 A AR P040104413A AR P040104413 A ARP040104413 A AR P040104413A AR 046728 A1 AR046728 A1 AR 046728A1
- Authority
- AR
- Argentina
- Prior art keywords
- transcription factor
- maf
- short form
- glaucoma
- cyclin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se ha identificado laregulación en ascenso de la versión de la forma corta del factor de transcripción de c-Maf en las células de la red trabecular tratadas con esteroides y tratadas con el factor de crecimiento transformante b 2, y está presente en niveles elevados en las células de la red trabecular glaucomatosas a diferencia de las normales y en el tejido de la cabeza del nervio óptico glaucomatoso y no en el normal. La expresión del factor de transcripción de la forma corta de c-Maf en estas condiciones indica un rol causal o efector del factor en la patogénesis del glaucoma primario de ángulo abierto y en el glaucoma inducido por esteroides. Se provoca el antagonismo de la expresión y/o actividad del factor de transcripción de la forma corta de c-Maf en la red trabecular u otro tejido ocular con el fin de inhibir o mitigar la patogénesis del glaucoma. Entre los antagonistas se cuentan los inhibidores de la quinasa dependiente de ciclina 2. Análogos de purina, como por ejemplo purvalanol y los inhibidores de la quinasa de pendiente de ciclina 2 sin base de purina. Reivindicación 1: Una composición para el tratamiento del glaucoma primario de ángulo abierto o glaucoma inducido por esteroides, composición que comprende un antagonista del factor de transcripción de la forma corta de c-Maf y un vehículo aceptable. Reivindicación 2: Una composición de acuerdo con la reivindicación 1, en la cual el antagonista del factor de transcripción de la forma corta de c-Maf comprende un análogo de purina con actividad inhibitoria de la quinasa dependiente de la ciclina cdk2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53180103P | 2003-12-22 | 2003-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046728A1 true AR046728A1 (es) | 2005-12-21 |
Family
ID=34738702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104413A AR046728A1 (es) | 2003-12-22 | 2004-11-26 | Antagonistas de factor de transcripcion de la forma corta de c-maf para el tratamiento del glaucoma |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050159432A1 (es) |
EP (1) | EP1696928A1 (es) |
JP (1) | JP2007515426A (es) |
KR (1) | KR20060110301A (es) |
CN (1) | CN1886138A (es) |
AR (1) | AR046728A1 (es) |
AU (1) | AU2004308938B2 (es) |
BR (1) | BRPI0418033A (es) |
CA (1) | CA2548035A1 (es) |
MX (1) | MXPA06007062A (es) |
RU (1) | RU2370267C2 (es) |
TW (1) | TW200526224A (es) |
UY (1) | UY28660A1 (es) |
WO (1) | WO2005063252A1 (es) |
ZA (1) | ZA200604576B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004308911B2 (en) * | 2003-12-22 | 2010-08-26 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
ZA200604862B (en) * | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
AU2007322261B2 (en) * | 2006-11-01 | 2014-01-23 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
US20080153903A1 (en) * | 2006-12-22 | 2008-06-26 | Alcon Manufacturing, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
US7682789B2 (en) * | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
DK2167963T3 (da) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymerbærere til immunhistokemi og in situ-hybridisering |
ES2906426T3 (es) | 2008-06-05 | 2022-04-18 | Ventana Med Syst Inc | Composición para procesamiento histoquímico |
USPP22463P3 (en) * | 2010-02-16 | 2012-01-17 | Menachem Bornstein | Gypsophila plant named ‘Pearl Blossom’ |
WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
EP2906718B1 (en) | 2012-10-12 | 2019-05-15 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf |
US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
WO2014140933A2 (en) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Method for the prognosis and treatment of cancer metastasis |
US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
CN105980576B (zh) | 2013-10-09 | 2021-07-16 | 生物医学研究机构基金会 | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 |
DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
JP2021504339A (ja) | 2017-11-22 | 2021-02-15 | インバイオモーション エセ.エレ. | c−MAFの状態に基づく乳がんの治療的処置 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質p160 |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
WO1997023222A1 (en) * | 1995-12-21 | 1997-07-03 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
JP3834663B2 (ja) * | 1996-02-02 | 2006-10-18 | 株式会社デ・ウエスタン・セラピテクス研究所 | イソキノリン誘導体及び医薬 |
US5798380A (en) * | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US6218410B1 (en) * | 1996-08-12 | 2001-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicines comprising Rho kinase inhibitor |
US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
WO1999007705A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
AU2001277285A1 (en) * | 2000-08-09 | 2002-02-18 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
PL378030A1 (pl) * | 2002-04-30 | 2006-02-20 | Alcon, Inc. | Czynniki które regulują, hamują lub modulują działanie i/lub wyrażanie czynnika wzrostowego tkanki łącznej (CTGF), jako wyjątkowe środki do obniżania ciśnienia śródgałkowego i leczenia retinopatii jaskrowej/neuropatii nerwu wzrokowego |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
MXPA05002493A (es) * | 2002-09-05 | 2005-05-27 | Neurosearch As | Derivados de diarilurea y su uso como bloqueadores del canal del cloro. |
US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
-
2004
- 2004-11-15 TW TW093134904A patent/TW200526224A/zh unknown
- 2004-11-26 AR ARP040104413A patent/AR046728A1/es not_active Application Discontinuation
- 2004-12-08 UY UY28660A patent/UY28660A1/es not_active Application Discontinuation
- 2004-12-21 RU RU2006126638/14A patent/RU2370267C2/ru not_active IP Right Cessation
- 2004-12-21 EP EP04815051A patent/EP1696928A1/en not_active Withdrawn
- 2004-12-21 WO PCT/US2004/042930 patent/WO2005063252A1/en active Application Filing
- 2004-12-21 BR BRPI0418033-0A patent/BRPI0418033A/pt not_active IP Right Cessation
- 2004-12-21 CA CA002548035A patent/CA2548035A1/en not_active Abandoned
- 2004-12-21 AU AU2004308938A patent/AU2004308938B2/en not_active Ceased
- 2004-12-21 JP JP2006545577A patent/JP2007515426A/ja active Pending
- 2004-12-21 KR KR1020067010098A patent/KR20060110301A/ko not_active Application Discontinuation
- 2004-12-21 MX MXPA06007062A patent/MXPA06007062A/es not_active Application Discontinuation
- 2004-12-21 CN CNA200480035441XA patent/CN1886138A/zh active Pending
- 2004-12-21 US US11/018,283 patent/US20050159432A1/en not_active Abandoned
- 2004-12-21 ZA ZA200604576A patent/ZA200604576B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0418033A (pt) | 2007-04-17 |
TW200526224A (en) | 2005-08-16 |
RU2370267C2 (ru) | 2009-10-20 |
CN1886138A (zh) | 2006-12-27 |
ZA200604576B (en) | 2007-11-28 |
MXPA06007062A (es) | 2006-09-04 |
JP2007515426A (ja) | 2007-06-14 |
CA2548035A1 (en) | 2005-07-14 |
RU2006126638A (ru) | 2008-01-27 |
UY28660A1 (es) | 2005-07-29 |
AU2004308938B2 (en) | 2011-06-23 |
US20050159432A1 (en) | 2005-07-21 |
WO2005063252A1 (en) | 2005-07-14 |
KR20060110301A (ko) | 2006-10-24 |
EP1696928A1 (en) | 2006-09-06 |
AU2004308938A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046728A1 (es) | Antagonistas de factor de transcripcion de la forma corta de c-maf para el tratamiento del glaucoma | |
ECSP066520A (es) | Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso | |
DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
PE20040781A1 (es) | Compuestos de purina como ligandos del receptor cannabinoide | |
De Simone et al. | A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis | |
AR051472A1 (es) | Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares | |
CR20110131A (es) | Derivados de prostaglandinas | |
CO5640076A2 (es) | Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento | |
GT200000168A (es) | Compuestos farmaceuticamente activos. | |
PE20060464A1 (es) | Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales | |
ECSP067123A (es) | Antagonistas de nk1 | |
ECSP055684A (es) | Antagonistas del receptor opiode | |
UY30060A1 (es) | Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos | |
PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
UY29527A1 (es) | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. | |
PE20080053A1 (es) | Composiciones oftalmicas de alcaftadina | |
AR063158A1 (es) | Asenapina amorfa,p rocesos para prepararla, composiciones farmaceuticas solidas que la contienen y su uso para tratar trastornos del sistema nervioso central. | |
UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
AR056814A1 (es) | Composiciones farmacéuticas | |
AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
CO6251360A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
AR042312A1 (es) | Derivado hemisulfato de azido citosina cristalino anhidro | |
ES2164465T3 (es) | Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. | |
UY28524A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |